Company intelligence / Profile preview

Minvasys

Ownership: Private
Development stage: Commercial

Overview

Minvasys has developed and commercialized interventional cardiology devices such as the DEVOIR Sirolimus-Coated Balloon and Danubio Paclitaxel-Eluting Balloon. Clinical trials have demonstrated safety and efficacy for treating in-stent restenosis, bifurcation lesions, small vessel disease, and de novo bifurcation lesions in native coronary arteries. The DEVOIR balloon is CE-marked; several studies are completed or ongoing.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

2 assets

Amazonia Pax

Commercial

Indications: Coronary artery disease

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Minvasys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minvasys.

Explore the full profile